UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 58 filers reported holding UNIQURE NV in Q1 2016. The put-call ratio across all filers is 1.87 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $268,000 | -71.4% | 7,100 | -82.2% | 0.02% | -73.3% |
| Q1 2018 | $937,000 | -39.6% | 39,900 | -75.3% | 0.06% | -27.7% |
| Q3 2017 | $1,551,000 | -3.7% | 161,600 | -37.9% | 0.08% | -16.2% |
| Q2 2017 | $1,610,000 | -9.3% | 260,100 | -15.3% | 0.10% | -11.6% |
| Q1 2017 | $1,775,000 | -10.8% | 307,200 | -13.6% | 0.11% | -31.7% |
| Q4 2016 | $1,991,000 | -6.7% | 355,700 | +27.4% | 0.16% | -5.2% |
| Q3 2016 | $2,135,000 | -23.8% | 279,100 | -26.6% | 0.17% | -34.0% |
| Q2 2016 | $2,803,000 | -20.3% | 380,400 | +28.5% | 0.26% | -26.2% |
| Q1 2016 | $3,516,000 | -8.0% | 296,000 | +28.1% | 0.36% | -27.1% |
| Q4 2015 | $3,822,000 | +513.5% | 231,100 | +657.7% | 0.49% | +501.2% |
| Q3 2015 | $623,000 | -55.4% | 30,500 | -41.1% | 0.08% | -58.5% |
| Q2 2015 | $1,398,000 | +11.7% | 51,800 | 0.0% | 0.20% | +11.4% |
| Q1 2015 | $1,252,000 | +406.9% | 51,800 | +210.2% | 0.18% | +316.7% |
| Q4 2014 | $247,000 | – | 16,700 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |